Emiliano Buitrago1, Ursula Winter1,2, Gustavo Williams3, Marcelo Asprea3, Guillermo Chantada4, Paula Schaiquevich1,2. 1. 1 Clinical Pharmacokinetics Unit, Hospital de Pediatría JP Garrahan , Buenos Aires, Argentina . 2. 2 National Scientific and Technical Research Council, CONICET , Buenos Aires, Argentina . 3. 3 Animal Facility Laboratory, Hospital de Pediatria JP Garrahan , Buenos Aires, Argentina . 4. 4 Department of Hematology-Oncology and Ophthalmology, Hospital de Pediatria JP Garrahan , Buenos Aires, Argentina .
Abstract
PURPOSE: Although widely used for vitreous seed control in retinoblastoma patients, currently there are no data on melphalan pharmacokinetics after intravitreal injections. Therefore, in this study, we characterized the ocular and systemic disposition of melphalan after intravitreal injection in the rabbit eye. METHODS: New Zealand rabbits received a single intravitreal injection of 15 μg of melphalan. Vitreous, aqueous, retina, and blood samples were collected at different times up to 12 h after the injection. Melphalan was quantitated in the biological samples using a validated high-performance liquid-chromatography technique and pharmacokinetic parameters were calculated by means of compartmental models. RESULTS: Model-predicted melphalan maximum vitreous, aqueous, and retina concentrations were 7.8 μg/mL, 0.024 μg/mL, and 9.8 μg/g tissue, respectively, attained immediately and at 0.8 and 0.25 h after intravitreal injection. Melphalan vitreous concentrations were higher than 0.3 μg/mL for 5 h after dosing. The elimination half-life from the vitreous, aqueous humor, and retina was 1.0, 0.2, and 1.2 h, respectively. Aqueous exposure [area under the curve (AUC)] was only 0.7% of that of the vitreous AUC. Melphalan concentrations in the retina were still detectable 12 h after dosing, while plasma exposure was under the limit of quantitation. CONCLUSION: Intravitreal administration of 15 μg melphalan leads to pharmacological vitreous levels with low aqueous exposure. Melphalan concentrations in the retina were measurable up to 12 h after dosing, but we report nondetectable systemic exposure in the rabbit. The results correlate with the clinical features of retinoblastoma patients that show control of vitreous seeds without systemic toxicity using intravitreal melphalan.
PURPOSE: Although widely used for vitreous seed control in retinoblastomapatients, currently there are no data on melphalan pharmacokinetics after intravitreal injections. Therefore, in this study, we characterized the ocular and systemic disposition of melphalan after intravitreal injection in the rabbit eye. METHODS:New Zealand rabbits received a single intravitreal injection of 15 μg of melphalan. Vitreous, aqueous, retina, and blood samples were collected at different times up to 12 h after the injection. Melphalan was quantitated in the biological samples using a validated high-performance liquid-chromatography technique and pharmacokinetic parameters were calculated by means of compartmental models. RESULTS: Model-predicted melphalan maximum vitreous, aqueous, and retina concentrations were 7.8 μg/mL, 0.024 μg/mL, and 9.8 μg/g tissue, respectively, attained immediately and at 0.8 and 0.25 h after intravitreal injection. Melphalan vitreous concentrations were higher than 0.3 μg/mL for 5 h after dosing. The elimination half-life from the vitreous, aqueous humor, and retina was 1.0, 0.2, and 1.2 h, respectively. Aqueous exposure [area under the curve (AUC)] was only 0.7% of that of the vitreous AUC. Melphalan concentrations in the retina were still detectable 12 h after dosing, while plasma exposure was under the limit of quantitation. CONCLUSION: Intravitreal administration of 15 μg melphalan leads to pharmacological vitreous levels with low aqueous exposure. Melphalan concentrations in the retina were measurable up to 12 h after dosing, but we report nondetectable systemic exposure in the rabbit. The results correlate with the clinical features of retinoblastomapatients that show control of vitreous seeds without systemic toxicity using intravitreal melphalan.
Authors: David H Abramson; Xunda Ji; Jasmine H Francis; Federica Catalanotti; Scott E Brodie; Larissa Habib Journal: Br J Ophthalmol Date: 2018-06-06 Impact factor: 4.638
Authors: M J Del Sole; M Clausse; P Nejamkin; B Cancela; M Del Río; G Lamas; F Lubieniecki; J H Francis; D H Abramson; G Chantada; P Schaiquevich Journal: Exp Eye Res Date: 2022-03-08 Impact factor: 3.770
Authors: Jessica V Kaczmarek; Carley M Bogan; Janene M Pierce; Yuankai K Tao; Sheau-Chiann Chen; Qi Liu; Xiao Liu; Kelli L Boyd; M Wade Calcutt; Thomas M Bridges; Craig W Lindsley; Debra L Friedman; Ann Richmond; Anthony B Daniels Journal: Invest Ophthalmol Vis Sci Date: 2021-11-01 Impact factor: 4.799
Authors: Paula Schaiquevich; Jasmine H Francis; María Belén Cancela; Angel Montero Carcaboso; Guillermo L Chantada; David H Abramson Journal: Front Oncol Date: 2022-04-01 Impact factor: 5.738